Synta Pharma (SNTA) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Synta Reports Second Quarter 2015 Financial Results
August 6, 2015 7:00 AM EDT- Phase 3 GALAXY-2 Trial on Track for Interim Analysis by Year End 2015 -
- Webcast and Conference Call Today, August 6, at 10:00 AM ET -
LEXINGTON, Mass.--(BUSINESS WIRE)-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the second quarter ended June 30, 2015 and provided a pipeline update.
The ganetespib development program is approaching its first key milestone, with the Phase 3 GALAXY-2 trial in non-small cell lung cancer nearing its first interim analysis, which is anticipated by year end, followed by the second... More
